Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea.

[12] Since 2020, Samsung Biologics has expanded its United States operations, opening offices in New Jersey[13] and San Francisco[14] to more closely support U.S. biopharmaceutical companies across both coasts.

As of June 2024, Samsung Biologics' CEO John Rim reported active partnerships with 16 of the top 20 largest biopharmaceutical companies.

[3] A month later, Samsung Biologics entered two deals with Pfizer worth a combined $897 million to produce biosimilar products ranging from oncology and inflammation to immunotherapy at its Plant 4.

In 2023, Samsung Biologics announced a multi-year agreement with European venture capital firm Kurma Partners to support its portfolio companies through development, manufacturing, and de-risking services.

[31] The fund, managed by Samsung Ventures, aims to foster the growth of next-generation technologies, such as gene therapies and ADCs.